A vaccine developed by Quebec-based Medicago Inc. has shown greater than 70-per-cent efficacy against a range of COVID-19 variants in a large-scale clinical trial, the company recently said.
The outcome bolsters Medicago’s bid to become the first COVID-19 vaccine maker in Canada to get a product to market for use either as a booster shot or as a first vaccine in places that remain critically unprotected from the disease.